Skip to content

Epidural and Intravenous Patient-Controlled Analgesia Following Lumbar Spinal Fusion Surgery

A Comparison of Epidural and Intravenous Patient-Controlled Analgesia Following Lumbar Spinal Fusion Surgery: A Prospective Randomized Study

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03115151
Enrollment
46
Registered
2017-04-14
Start date
2017-05-08
Completion date
2023-04-04
Last updated
2023-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Brief summary

Postoperative analgesia following spine surgery is difficult to manage. Current treatment modalities rely heavily on opioid analgesics with all of the inherent limitations and side effects. While current best practice focuses on a 'multimodal approach' (i.e. using multiple different drugs and techniques to control pain after surgery), there is no consensus regarding which components of this multimodal therapy provide optimal analgesia. This prospective randomized study will enroll patients undergoing elective Lumbar Spinal Fusion Surgery at Zale Lipshy University Hospital. The primary objective is to determine the comparative efficacy of epidural analgesia, as compared with intravenous (IV) patient-controlled analgesia (PCA), on post-operative analgesia.

Detailed description

Study Design: Prospective study of 58 subjects undergoing elective Lumbar Spinal Fusion (1-3 levels- posterior approach) at UTSW Zale Lipshy University Hospital with: 1. Continuous Lumbar Epidural Analgesia (Patient-Controlled Epidural Analgesia- PCEA groups) 2. Intravenous Patient-Controlled Analgesia (IV PCA) Study Interventions - The intervention to be evaluated in this study is epidural analgesia using an infusion of 0.0625% bupivacaine plus fentanyl 2mcg/ml. The epidural infusion will be continued until it is appropriate to transition the patient to a regimen of oral pain medications. Duration of epidural catheter will be 72 hours a postoperatively. For subjects in the IV PCA group, the intervention will include post-operative IV PCA with Hydromorphone. Epidural catheters will be placed by the spine surgeon under direct visualization intra-operatively prior to closing the surgical incision. Intra-operative epidural catheter placement by the spine surgeon will typically be done at the upper end of the dural exposure/laminectomy. Epidurals will be assessed for efficacy/function in the recovery room post-operatively by the APS, and then daily on the floor post-operatively (unless contacted by the floor nurse regarding specific concerns). Visual analog pain scale (VAS) will be used to evaluate degree of pain at 3, 24, 48, and 72 hours after surgery. Additionally, both the IV PCA and the epidural PCEA groups may be given additional rescue pain medications as needed in the recovery room, and these may be continued through the post-operative period on the floor. Total study duration is approximately 50 days, which starts from operating room admission for spinal fusion surgery to the first follow-up visit after discharge.

Interventions

DRUGBupivacaine

Bupivacaine (0.0625%) will be combined with fentanyl for postoperative epidural analgesia via a lumbar epidural catheter

DRUGHydromorphone

Hydromorphone will be given continuous infusion for intravenous patient controlled analgesia (syringe 25 mg/50 mL).

DRUGFentanyl

Fentanyl (2 mcg/ml) will be given via epidural route together with bupivacaine.

Sponsors

University of Texas Southwestern Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Adult subjects aged 18 years or older * Scheduled for elective posterior lumbar spinal fusion surgery between 1 and 3 levels

Exclusion criteria

* Baseline cognitive deficits sufficient to make objective pain self-assessments unreliable in the estimation of the Study Investigators. * Immunocompromised subject * Coagulopathy * Severe liver and renal dysfunction * Preoperative neurological deficits * The dura damage during surgery * Inability to follow directions or comprehend the English language. * Females who are pregnant as determined by positive pregnancy test on or before the day of surgery. * Prisoners. * Patient refusal to provide informed consent. * Allergy to amide local anesthetics (lidocaine, bupivacaine, ropivacaine) or opioid (fentanyl) allergy if patient assigned epidural analgesia. * Hydromorphone allergy if patient assigned IV PCA

Design outcomes

Primary

MeasureTime frameDescription
Visual Analog Pain Score (VAS)VAS score at postoperative 24 hoursPostoperative Visual Analog Pain Score following lumbar fusion surgery. VAS on the scale 0 to 100 (0= no pain, 100= worst pain).

Countries

United States

Participant flow

Participants by arm

ArmCount
Patient-Controlled Epidural Analgesia
Bupivacaine and fentanyl infusion via Continuous Lumbar Epidural Analgesia during postoperative 72 hours Bupivacaine: Bupivacaine (0.0625%) will be combined with fentanyl for postoperative epidural analgesia via a lumbar epidural catheter Fentanyl: Fentanyl (2 mcg/ml) will be given via epidural route together with bupivacaine.
17
Intravenous Patient-controlled Analgesia
Postoperative intravenous patient-controlled analgesia (IV PCA) with Hydromorphone Hydromorphone: Hydromorphone will be given continuous infusion for intravenous patient controlled analgesia (syringe 25 mg/50 mL).
18
Total35

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyEpidural catheter removal10
Overall StudyIntervention discontinue due to clinical condition22
Overall StudyIntervention not received according to the protocol.11
Overall StudyPhysician Decision10
Overall StudyRandomization not applied11
Overall StudyWithdrawal by Subject01

Baseline characteristics

CharacteristicTotalPatient-Controlled Epidural AnalgesiaIntravenous Patient-controlled Analgesia
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
21 Participants12 Participants9 Participants
Age, Categorical
Between 18 and 65 years
14 Participants5 Participants9 Participants
Age, Continuous63.37 years
STANDARD_DEVIATION 11.36
66.8 years
STANDARD_DEVIATION 6
60 years
STANDARD_DEVIATION 14
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants1 Participants1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
33 Participants16 Participants17 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Preoperative Pain Score37.37 units on a scale (0 to 100)
STANDARD_DEVIATION 24.57
39.47 units on a scale (0 to 100)
STANDARD_DEVIATION 23.09
35.38 units on a scale (0 to 100)
STANDARD_DEVIATION 26.4
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
4 Participants2 Participants2 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants1 Participants0 Participants
Race (NIH/OMB)
White
30 Participants14 Participants16 Participants
Sex: Female, Male
Female
26 Participants11 Participants15 Participants
Sex: Female, Male
Male
9 Participants6 Participants3 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 190 / 21
other
Total, other adverse events
0 / 190 / 21
serious
Total, serious adverse events
0 / 190 / 21

Outcome results

Primary

Visual Analog Pain Score (VAS)

Postoperative Visual Analog Pain Score following lumbar fusion surgery. VAS on the scale 0 to 100 (0= no pain, 100= worst pain).

Time frame: VAS score at postoperative 24 hours

Population: Spinal fusion surgeries level 1 to 3.

ArmMeasureValue (MEAN)Dispersion
Patient-Controlled Epidural AnalgesiaVisual Analog Pain Score (VAS)40.23 units on a scaleStandard Deviation 24.69
Intravenous Patient-controlled AnalgesiaVisual Analog Pain Score (VAS)54.27 units on a scaleStandard Deviation 25.41

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026